A recent study indicates that individuals who stop using new GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass at a significantly accelerated pace than those who halt traditional diet and exercise plans.
Research printed in a prominent health publication shows that while overweight individuals often shed a large proportion of their total mass while on the medication, the weight is regained at an estimated rate of nearly a kilo each month once they quit.
"Individuals using such treatments must be cognizant of the danger of fast rebound weight gain when the therapy concludes," stated researcher Dr. Susan Jebb.
That rate of recovery suggests a reversion to pre-treatment weight in about one and a half years.
Analyzing Treatments
The study, which examined dozens of studies involving over 9,000 of participants, compared the outcomes of the injectable medications with older methods.
The team point out that people who shed pounds through diet and exercise usually have a slower creep back—approximately 100 grams monthly—after stopping.
Understanding the Rapid Rebound
Nutrition scientists propose the mode of action of the drugs explains the heightened regain.
The injections imitate a natural hormone called GLP-1, which controls feelings of fullness.
"Sustained high doses of the hormone levels far above than the body's typical production might result in the system to generate a reduced amount of its own natural hormone, and may also reduce responsiveness to its effects," noted Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this GLP-1 'fix' means appetite is uncontrolled, making excessive eating a significant risk."
An Ongoing Condition?
Medical guidelines advise the injections for people with obesity-related medical conditions, accompanied by prescribed diet and exercise modifications.
Many experts say that, due to the significant potential of relapse, the therapy is often long-term.
This opinion is echoed by pharmaceutical companies, who state that the results "highlight the persistent character of obesity," similar to managing conditions like high blood pressure.
User Accounts
Users who have stopped the medication explain a intense resurgence of appetite.
"It felt as if a trigger that goes on and you become extremely hungry," described a patient.
This difficulty is worsened if individuals have not developed permanent dietary or behavioural changes during therapy.
Significant Interest
Survey data indicate that a significant number of adults in the UK have used weight-loss jabs in the past year, with desire remaining high.
- Use is more common among females compared to males.
- The 40s and 50s age group shows the greatest usage rates.
- Many access the medications through private healthcare rather than public health services.
In conclusion, researchers caution that while GLP-1 drugs are effective tools for weight loss, they are not a standalone fix and long-term success relies on integrated behavioural support.
